The expression of @entity995 and @entity588 proteins was investigated in 135 @entity259 (130 @entity1377 and @entity189 ) by the immunohistochemical technique with @entity995 and @entity588 monoclonal antibodies. The results were as follows: 1) @entity995 protein nuclear staining was shown in 117 of the 135 @entity259 (87%). @entity588 protein staining was shown in 82 of the @entity189 (61%). 2) There was a higher incidence of recurrence in @entity995 -negative cases than in @entity995 -positive cases (chi 2 test p = 0.001). But there is no significant relationship between the incidence of recurrence and the results of @entity588 staining (chi 2 test p = 0.287). 3) The expression of @entity995 protein was related to age and clinical N and M categories. @entity588 protein expression was related to clinical T categories. 4) The 10-year overall survival rate for @entity995 -positive @entity1 was higher than that for negative @entity1 (long-rank test p < 0.0001). But the survival rate was not associated with @entity588 expression (log-rank test p = 0.3). Our results suggest that assessment of @entity995 protein expression by the immunohistochemical technique may be useful to determine the possibility of recurrence and to predict the outcome of @entity259 . We think that assessment of @entity995 protein expression by the immunohistochemical technique can be applied as a more sensitive prognostic factor.

[An immunohistochemical study of RB tumor suppressor gene protein and @entity588 gene protein in XXXX of the thyroid gland].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1377 :: ('MESH:D002291', 'Disease') :: ['papillary carcinomas'] @entity588 :: ('596', 'Gene') :: ['bcl-2', 'Bcl-2'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomas', 'five follicular carcinomas'] @entity259 :: ('MESH:D013964', 'Disease') :: ['thyroid carcinomas'] @entity995 :: ('MESH:D012175', 'Disease') :: ['RB']
@entity189 :: (MESH:D002277,Disease) :: ['carcinomas']
